f2903ac6-88e3-4653-a966-ab593fba51bf
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- ANGIOGENESIS+0.400
- COAGULATION+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
- APICAL_SURFACE+0.300
- COMPLEMENT+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
Top 10 suppressed
- MITOTIC_SPINDLE-0.500
- MYC_TARGETS_V2-0.500
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- PROTEIN_SECRETION-0.400
- ADIPOGENESIS-0.300
- DNA_REPAIR-0.300
- FATTY_ACID_METABOLISM-0.300
- GLYCOLYSIS-0.300
- MYC_TARGETS_V1-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-22-1005-01A-01R-0692-07 | — | cohortMD2 | 0.921 |
| 2 | SRR1394343 | GTEX | — | 0.921 |
| 3 | SRR1319539 | GTEX | — | 0.915 |
| 4 | 2d8d97e6-b599-4444-8e11-73adb55be0be | — | — | 0.913 |
| 5 | f426318a-9c1a-4476-a087-2b3a84096f5c | — | — | 0.910 |
| 6 | 3d89c16f-8045-4861-a82c-9f4624292284 | — | — | 0.908 |
| 7 | SRR8392886 | — | cohortA1 | 0.908 |
| 8 | SRR1472301 | GTEX | — | 0.907 |
| 9 | SRR1389059 | GTEX | — | 0.906 |
| 10 | SRR1415832 | GTEX | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |